Please provide your email address to receive an email when new articles are posted on . Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the neoadjuvant regimen had similar median OS as those who received upfront surgery and ...

Researchers find that FOLFIRINOX, a chemotherapy used for pancreatic cancer, may improve survival in advanced biliary tract cancer patients BUSAN, South Korea, Nov. 28, 2025 /PRNewswire/ -- A new ...

STOCKHOLM, June 8, 2021 /PRNewswire/ -- Cantargia AB today announce that the clinical trial application to investigate the antibody nadunolimab (CAN04) in combination with the FOLFIRINOX chemotherapy ...

The chemotherapy regimen known as FOLFIRINOX produces an "impressive clinical response" in locally advanced pancreatic ductal adenocarcinoma, according to the authors of a new small, retrospective, ...

Among patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, neoadjuvant FOLFIRINOX showed comparable overall survival to neoadjuvant gemcitabine-based chemoradiotherapy, ...

Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all ...

MELBOURNE, Australia, May 29, 2023 /PRNewswire/ -- Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK ...

Surgical resection and peri-operative chemotherapy for colorectal cancer (CRC) liver metastases in routine clinical practice: A population-based outcomes study. This is an ASCO Meeting Abstract from ...

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2 ...